Emmedingen/Braunschweig, September 2023 – BioCopy and YUMAB announce a partnership to fight cancer by accelerating the develoment of highly specific antibodies against pHLA targets.
BioCopy will use its safeTY-engager® pHLA screening platform to characterize drug candidates in great depth. YUMAB will develop antibodies against these targets that bind with high specificity to tumor-associated pHLA complexes, thereby marking cells as T cell engagers for elimination by the immune system. The project is funded by the German Federal Ministry of Education and Research (BMBF) with a total of EUR 1.1 million.
Read press release (English)
Read press release (German)